Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Panicha Chantrapanichkul et al, adding:
”Polycystic ovary syndrome and hormonal contraception: how do estetrol/drospirenone and drospirenone-only compare on clotting activity?
Combined oral contraceptives are first-line treatment for polycystic ovary syndrome (PCOS), but the risk of venous thromboembolism remains a concern. Estetrol/drospirenone (E4/DRSP) has shown a more favourable thrombin generation profile than ethinyl estradiol-based pills, yet direct comparison with a progestin-only pill was missing. A new randomised, double-blind trial in RPTH Journal fills that gap.
Key findings from 66 women 🇹🇠with PCOS treated for 12 weeks:
- Both regimens increased endogenous thrombin potential and peak height on the thrombin generation assay, with no significant difference between groups
- The ETP-thrombomodulin ratio rose to a similar extent in both groups (median plus 0.14 with E4/DRSP vs plus 0.13 with DRSP-only; P equal.74)
- E4/DRSP significantly reduced hirsutism (modified Ferriman–Gallwey score; P less than .001)
- DRSP-only was associated with fewer scheduled bleeding days across 3 cycles
- Acne, waist-to-hip ratio, and treatment satisfaction were comparable, with no serious adverse events
Still, the results are reassuring: E4/DRSP did not increase coagulation activity beyond a progestin-only pill, while offering an added benefit on hirsutism, supporting its consideration as a contraceptive option for women with PCOS.”
Title: Effects of estetrol/drospirenone vs drospirenone-only on thrombin generation in women with polycystic ovary syndrome: a randomized, double-blind, controlled trial
Authors: Panicha Chantrapanichkul, Paveenutch Wiwatboworn, Manee Rattanachaiyanont, Prasong Tanmahasamut, Thanyarat Wongwananuruk, Wichapanun Surasang, Theera Ruchutrakool, Yingyong Chinthammitr, Bundarika Suwanawiboon, Tarinee Rungjirajittranon

More posts featuring RPTH Journal on Hemostasis Today.
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia